Ryan P Knox
Biographic Data
| ID | 8450629 |
|---|---|
| NAME | Ryan P Knox |
| GIVEN NAMES | Ryan P |
| FAMILY NAME | Knox |
| SIGNATURE | KNOX R P |
| AFFILIATIONS | Yale Law School, New Haven, Connecticut |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 2 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
Outcomes of the 340B Drug Pricing Program
In this scoping review of the 340B program, we found that the 340B program was associated with financial benefits for hospitals, clinics, and pharmacies; improved access to health care services for patients; and substantial costs to manufacturers. Increased transparency regarding the use of 340B program revenue and strengthened rulemaking and enforcement authority for the Health Resources and Services Administration would support compliance and h…
Independent Pharmacies Gain Unanimous Victory in Recent US Supreme Court Case
Independent pharmacies across the country-particularly those in rural areas-have struggled financially in recent years. Between 2003 and 2018, 16.1% of independent pharmacies in rural areas closed their doors. Pharmacies often experience financial hardship because reimbursements rates are below the costs of acquiring and dispensing some drugs, with some pharmacies reporting as much as 80% of reimbursements being below the cost to dispense. 1 Thes…
No prominent works on this page.
Independent Pharmacies Gain Unanimous Victory in Recent US Supreme Court Case
Independent pharmacies across the country-particularly those in rural areas-have struggled financially in recent years. Between 2003 and 2018, 16.1% of independent pharmacies in rural areas closed their doors. Pharmacies often experience financial hardship because reimbursements rates are below the costs of acquiring and dispensing some drugs, with some pharmacies reporting as much as 80% of reimbursements being below the cost to dispense. 1 Thes…
Outcomes of the 340B Drug Pricing Program
In this scoping review of the 340B program, we found that the 340B program was associated with financial benefits for hospitals, clinics, and pharmacies; improved access to health care services for patients; and substantial costs to manufacturers. Increased transparency regarding the use of 340B program revenue and strengthened rulemaking and enforcement authority for the Health Resources and Services Administration would support compliance and h…
Law (2 works) · Law (2 works) · Political science (2 works) · Accounting (1 works) · Actuarial science (1 works) · Agency (philosophy (1 works) · Audit (1 works) · Business (1 works) · Drug pricing (1 works) · EconLit (1 works)